Abstract
Azathioprine is an efficient maintenance treatment of IBD, able to maintain a complete clinical and anatomical remission in about one third of patients. However there are concerns regarding its long term tolerance, particularly myelosuppression and malignancy. Azathioprine is not required in about one third of Crohn's Disease patients and more than half of Ulcerative Colitis patients who will experience a mild disease course. In patients with more severe disease, although anti-TNF agents are more powerful and act more rapidly, there is a subset of patients with moderate-to-severe IBD without important anatomical damage who may achieve a prolonged steroid-free clinical and anatomical remission on azathioprine monotherapy. It is thus advised to initiate azathioprine monotherapy in these intermediate cases, and to continue azathioprine if anatomical remission is achieved.
Keywords: Anti-TNF agents, azathioprine, Crohn's disease, mercaptopurine, ulcerative coilitis.
Current Drug Targets
Title:Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?
Volume: 14 Issue: 12
Author(s): Anne Bourrier, Philippe Seksik and Jacques Cosnes
Affiliation:
Keywords: Anti-TNF agents, azathioprine, Crohn's disease, mercaptopurine, ulcerative coilitis.
Abstract: Azathioprine is an efficient maintenance treatment of IBD, able to maintain a complete clinical and anatomical remission in about one third of patients. However there are concerns regarding its long term tolerance, particularly myelosuppression and malignancy. Azathioprine is not required in about one third of Crohn's Disease patients and more than half of Ulcerative Colitis patients who will experience a mild disease course. In patients with more severe disease, although anti-TNF agents are more powerful and act more rapidly, there is a subset of patients with moderate-to-severe IBD without important anatomical damage who may achieve a prolonged steroid-free clinical and anatomical remission on azathioprine monotherapy. It is thus advised to initiate azathioprine monotherapy in these intermediate cases, and to continue azathioprine if anatomical remission is achieved.
Export Options
About this article
Cite this article as:
Bourrier Anne, Seksik Philippe and Cosnes Jacques, Is There Still a Room for Azathioprine Monotherapy in Inflammatory Bowel Disease?, Current Drug Targets 2013; 14 (12) . https://dx.doi.org/10.2174/13894501113149990172
DOI https://dx.doi.org/10.2174/13894501113149990172 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Therapeutic Application of Melatonin in the Treatment of Melanoma: A Review
Current Cancer Therapy Reviews Recent Developments in Anti-Cancer Agents Targeting the Ras/Raf/ MEK/ERK Pathway
Recent Patents on Anti-Cancer Drug Discovery Ureas: Applications in Drug Design
Current Medicinal Chemistry Role of Tumor Microenvironment in Cancer Stem Cells Resistance to Radiotherapy
Current Cancer Drug Targets Raf Inhibitors as Therapeutic Agents Against Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Patents and the Development on Polymer based Nanomaterial (PAMAM Dendrimer) for Biomedical Applications
Recent Patents on Biomedical Engineering (Discontinued) Emerging Concepts on Inhibitors of Indoleamine 2,3-Dioxygenase in Rheumatic Diseases
Current Medicinal Chemistry Recent Advances and Approaches in Targeting Apoptosis Signaling Pathways for Anti-Cancer Therapeutics
Current Cancer Therapy Reviews Natural Molecules as Talented Inhibitors of Nucleotide Pyrophosphatases/ Phosphodiesterases (PDEs)
Current Topics in Medicinal Chemistry Scope of Nanotechnology-based Radiation Therapy and Thermotherapy Methods in Cancer Treatment
Current Cancer Drug Targets Has Selenium a Chemopreventive Effect on Hepatocellular Carcinoma?
Mini-Reviews in Medicinal Chemistry An Overview on Different Classes of Viral Entry and Respiratory Syncitial Virus (RSV) Fusion Inhibitors
Current Medicinal Chemistry In-Vitro Antiproliferative Activity of New Tetrahydroisoquinolines (THIQs) on Ishikawa Cells and their 3D Pharmacophore Models
Letters in Drug Design & Discovery Improving Cancer Therapeutics by Molecular Profiling
Current Drug Metabolism In Vivo Tumor Secretion Probing Via Ultrafiltration and Tissue Chamber:Implication for Anti-Cancer Drugs Targeting Secretome
Recent Patents on Anti-Cancer Drug Discovery Cutaneous Delivery of Natural Antioxidants: The Enhancement Approaches
Current Pharmaceutical Design Mycotherapy of Cancer: An Update on Cytotoxic and Antitumor Activities of Mushrooms, Bioactive Principles and Molecular Mechanisms of their Action
Current Topics in Medicinal Chemistry Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Soluble Factors of Amnion-Derived Cells in Treatment of Inflammatory and Fibrotic Pathologies
Current Stem Cell Research & Therapy Recent Advances in Small Molecule Inhibitors of VEGFR and EGFR Signaling Pathways
Current Topics in Medicinal Chemistry